CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation ("CEL SCI" or the "Company") today announced that during the month of June it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 848 as of June 30, 2016.
View full press release